Bradykinesia adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From February 2004 to June 2026, FDA received 5,749 adverse event reports that record the MedDRA preferred term Bradykinesia. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 508 reports in the 12 months to June 2026 and 580 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 982 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 508 (under 0.1%) record this term. Reports for male patients were 44% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 94 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Bradykinesia name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	38
Acetaminophen		53
Albuterol	beta2-Adrenergic agonist	29
Allopurinol	Xanthine oxidase inhibitor	37
Alprazolam	Benzodiazepine	144
Amantadine	Influenza A M2 protein inhibitor	35
Amlodipine	Calcium channel blocker	54
Aripiprazole	Atypical antipsychotic	91
Atorvastatin		50
Atorvastatin calcium	HMG-CoA reductase inhibitor	26
Avonex	Interferon beta	59
Benserazide Levodopa		32
Betahistine		30
Bromazepam		39
Buprenorphine	Partial opioid agonist	32
Carbidopa levodopa	Aromatic amino acid	803
Citalopram	Serotonin reuptake inhibitor	82
Clonazepam	Benzodiazepine	86
Clozapine	Atypical antipsychotic	79
Codeine		61
Dabigatran		32
Denosumab	RANK ligand inhibitor	27
Diazepam	Benzodiazepine	112
Donepezil		44
Duodopa		352
Duopa	Aromatic amino acid	48
Entacapone	Catechol-O-Methyltransferase inhibitor	25
Entresto	Angiotensin 2 receptor blocker	44
Escitalopram	Serotonin reuptake inhibitor	69
Foscarbidopa/foslevodopa		128
Furosemide	Loop diuretic	37
Gabapentin	Anti-epileptic agent	61
Gliclazide		44
Haloperidol	Typical antipsychotic	98
Humira		25
Hydrochlorothiazide	Thiazide diuretic	40
Hydroxyzine	Antihistamine	42
Ibrance	Kinase inhibitor	34
Ingrezza	Vesicular monoamine transporter 2 inhibitor	100
Isosorbide mononitrate	Nitrate vasodilator	33
Lacosamide		31
Lamotrigine	Anti-epileptic agent	36
Levetiracetam		46
Levomethadone		40
Levothyroxine		32
Lorazepam	Benzodiazepine	205
Lyrica		51
Metformin	Biguanide	56
Metoclopramide	Dopamine-2 receptor antagonist	78
Metoprolol	beta-Adrenergic blocker	35
Mirtazapine		108
Morphine	Opioid agonist	51
Morphine sulfate	Opioid agonist	28
Neupro	Nonergot dopamine agonist	48
Nordazepam		81
Nuplazid	Atypical antipsychotic	180
Olanzapine	Atypical antipsychotic	148
Omeprazole	Proton pump inhibitor	63
Ongentys	Catechol-O-Methyltransferase inhibitor	47
Orgovyx	Gonadotropin releasing hormone receptor antagonist	29
Oxazepam	Benzodiazepine	67
Oxcarbazepine	Anti-epileptic agent	42
Paroxetine	Serotonin reuptake inhibitor	60
Potassium chloride	Osmotic laxative	38
Pramipexole	Nonergot dopamine agonist	42
Prednisone	Corticosteroid	26
Pregabalin		95
Quetiapine	Atypical antipsychotic	218
Quetiapine fumarate	Atypical antipsychotic	66
Ramipril	Angiotensin converting enzyme inhibitor	53
Risperdal	Atypical antipsychotic	36
Risperidone	Atypical antipsychotic	153
Rivastigmine	Cholinesterase inhibitor	43
Rivotril		74
Ropinirole	Nonergot dopamine agonist	26
Rytary	Aromatic amino acid	37
Seroquel	Atypical antipsychotic	47
Sertraline	Serotonin reuptake inhibitor	112
Sinemet	Aromatic amino acid	69
Spironolactone	Aldosterone antagonist	35
Stalevo		27
Tavor		58
Tecfidera		76
Temazepam	Benzodiazepine	53
Topiramate		27
Tramadol		49
Tysabri	Integrin receptor antagonist	60
Valproic acid	Anti-epileptic agent	50
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	27
Vyalev		35
Xanax	Benzodiazepine	62
Xeljanz	Janus kinase inhibitor	88
Zolpidem	gamma-Aminobutyric acid A receptor positive modulator	77
Zolpidem tartrate	gamma-Aminobutyric acid A receptor positive modulator	34

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 43 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Bradykinesia name, in order of name
Class	Reports with this term
Aldosterone antagonist	45
Angiotensin 2 receptor blocker	75
Angiotensin converting enzyme inhibitor	73
Anti-epileptic agent	264
Antihistamine	55
Aromatic amino acid	1,009
Atypical antipsychotic	1,151
Benzodiazepine	763
beta-Adrenergic blocker	71
beta2-Adrenergic agonist	35
Biguanide	69
Calcium channel blocker	62
Catechol-O-Methyltransferase inhibitor	72
CD20-directed cytolytic antibody	37
Cholinesterase inhibitor	58
Corticosteroid	57
Dopamine-2 receptor antagonist	89
gamma-Aminobutyric acid A receptor positive modulator	114
Gonadotropin releasing hormone receptor antagonist	29
HMG-CoA reductase inhibitor	52
Influenza A M2 protein inhibitor	44
Insulin analog	28
Integrin receptor antagonist	62
Interferon beta	73
Janus kinase inhibitor	107
Kinase inhibitor	93
Loop diuretic	79
Mood stabilizer	69
Nitrate vasodilator	39
Nonergot dopamine agonist	146
Nonsteroidal anti-inflammatory drug	74
Opioid agonist	164
Osmotic laxative	38
Partial opioid agonist	32
Platinum-based drug	28
Proton pump inhibitor	107
RANK ligand inhibitor	27
Serotonin and norepinephrine reuptake inhibitor	56
Serotonin reuptake inhibitor	458
Thiazide diuretic	40
Typical antipsychotic	98
Vesicular monoamine transporter 2 inhibitor	113
Xanthine oxidase inhibitor	37

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Bradykinesia, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Bradykinesia
Age	Reports	Share
Under 2	8	0.1%
2 to 11	24	0.4%
12 to 17	76	1.3%
18 to 44	698	12.1%
45 to 64	1,136	19.8%
65 to 74	1,131	19.7%
75 and over	931	16.2%
Age not given	1,745	30.4%

Sex of the patient in the reports that record Bradykinesia
Sex	Reports	Share
Female	2,841	49.4%
Male	2,529	44%
Unknown or not given	379	6.6%

Age and sex are as the report gives them. 34.3% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Bradykinesia: adverse event reports that record this term. https://reportedreactions.com/reaction/bradykinesia/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Bradykinesia mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page